Similar articles for PMID: 23666932

Year	Number of Results
1995	1
1999	2
2000	1
2001	2
2002	3
2004	2
2005	4
2006	5
2007	7
2008	5
2009	6
2010	10
2011	14
2012	11
2013	12
2014	34
2015	21
2016	15
2017	7
2018	7
2019	7
2020	8
2021	2
2022	3
2023	2
2024	0

1

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. Garcês S, et al. Ann Rheum Dis. 2014 Jun;73(6):1138-43. doi: 10.1136/annrheumdis-2013-203296. Epub 2013 May 11. Ann Rheum Dis. 2014. PMID: 23666932

2

Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.

Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL. Chen DY, et al. Ann Rheum Dis. 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893. Epub 2014 Jan 17. Ann Rheum Dis. 2015. PMID: 24442879

3

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A. Dewedar AM, et al. Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13. Int J Rheum Dis. 2012. PMID: 22709496

4

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. Jamnitski A, et al. Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10. Ann Rheum Dis. 2011. PMID: 21068090 Clinical Trial.

5

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O. Zisapel M, et al. J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685. Epub 2014 Nov 15. J Rheumatol. 2015. PMID: 25399390

6

Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P. Fernández-Nebro A, et al. J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1. J Rheumatol. 2007. PMID: 17985409 Clinical Trial.

7

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; ARTIS group. Chatzidionysiou K, et al. Ann Rheum Dis. 2015 May;74(5):890-6. doi: 10.1136/annrheumdis-2013-204714. Epub 2014 Jan 15. Ann Rheum Dis. 2015. PMID: 24431398

8

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Finckh A, et al. Arthritis Rheum. 2007 May;56(5):1417-23. doi: 10.1002/art.22520. Arthritis Rheum. 2007. PMID: 17469098 Free article.

9

Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y. Matsudaira R, et al. J Rheumatol. 2011 Nov;38(11):2346-54. doi: 10.3899/jrheum.101295. Epub 2011 Oct 1. J Rheumatol. 2011. PMID: 21965648

10

Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.

Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL. Blom M, et al. J Rheumatol. 2011 Nov;38(11):2355-61. doi: 10.3899/jrheum.101324. Epub 2011 Sep 1. J Rheumatol. 2011. PMID: 21885487

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

161 results

Results by year